Enlivex Therapeutics (FRA:1BT) Short-Term Capital Lease Obligation : €0.32 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Short-Term Capital Lease Obligation?

Enlivex Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.32 Mil.

Enlivex Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Jun. 2023 (€0.62 Mil) to Sep. 2023 (€0.66 Mil) but then declined from Sep. 2023 (€0.66 Mil) to Dec. 2023 (€0.32 Mil).

Enlivex Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.55 Mil) to Dec. 2022 (€0.62 Mil) but then declined from Dec. 2022 (€0.62 Mil) to Dec. 2023 (€0.32 Mil).

Enlivex Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Enlivex Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Short-Term Capital Lease Obligation Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.11

0.17

0.55

0.62

0.32

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.62	0.64	0.62	0.66	0.32

Enlivex Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Enlivex Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (FRA:1BT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ENLV:USA ENLV:Israel

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (FRA:1BT) Headlines

No Headlines